Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.

International journal of molecular sciences - 14 Jan 2021

Ohmori Tohru, Yamaoka Toshimitsu, Ando Koichi, Kusumoto Sojiro, Kishino Yasunari, Manabe Ryou, Sagara Hironori

Abstract excerpt

The tyrosine kinase activity of epidermal growth factor receptors (EGFRs) plays critical roles in cell proliferation, regeneration, tumorigenesis, and anticancer resistance. Non-small-cell lung cancer patients who responded to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) and obtained survival benefits had somatic EGFR mutations. EGFR-TKI-related adverse events (AEs) are usually tolerable and manageable, although...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Afatinib
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Gefitinib

Share to Lung Diseases, Interstitial

Share to Lung Injury

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 33466795
DOI: 10.3390/ijms22020792
PMCID: PMC7829873

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.PMID 33466795Read ↗

Lung Cancer and Interstitial Lung DiseasesSemantic proximity Read ↗

Osimertinib-related Pulmonary Fibrosis, A case report and review of literatureSemantic proximity Read ↗

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations.Semantic proximity Read ↗

The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer.Semantic proximity Read ↗

Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib.Semantic proximity Read ↗

Interstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations.Semantic proximity Read ↗

EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment.Semantic proximity Read ↗

Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).Semantic proximity Read ↗

[Molecule pathology in the treatment of lung cancer-Interdisciplinary view of the importance in thoracic surgery].Semantic proximity Read ↗

EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment.Semantic proximity Read ↗

Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Association of cytokines levels with epidermal growth factor receptor mutation in lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.